Form 4: Director Emma Reeve Receives Stock Options in Whitehawk

Director Emma Reeve was granted 38,040 stock options in Whitehawk Therapeutics, Inc. with an exercise price of $4.16.

Summary

• Director Emma Reeve received a grant of 38,040 stock options on June 12, 2026.
• The options have an exercise price of $4.16 per share.
• The options are set to expire on June 12, 2036.
• Vesting occurs on the earlier of the one-year anniversary of the grant or the day before the next annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the reporting person remaining a Service Provider under the 2021 Equity Incentive Plan.

Future Outlook

The options vest in full after one year or upon the next annual meeting, whichever comes first, incentivizing the director's continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure leadership remains focused on long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical equity incentive plans for small-cap biotechnology companies.
• The use of a 10-year expiration term is standard for executive and director stock option awards.

Corporate Governance

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 12, 2027, or the day prior to the next annual meeting.

Key Dates

Keywords

Whitehawk Therapeutics, WHWK, Form 4, Insider Trading, Stock Options, Director Compensation